#None #Leo Cancer Care #Upright Therapy #IHH Healthcare

Collaboration Expansion in Cancer Care

In a significant development within the healthcare sector, IHH Healthcare has announced an expansion of its partnership with Leo Cancer Care, aimed at advancing upright cancer therapies in Asia. This collaboration seeks to introduce innovative upright radiotherapy solutions, including Leo's newly launched upright linear accelerators, known as Grace™, across IHH's extensive hospital network.

Commitment to Innovation and Patient Care

The partnership builds upon IHH's entry into the Upright Photon Alliance in 2024, reflecting a deep commitment to leveraging advanced technologies for better patient outcomes. By incorporating these upright solutions into their medical services, IHH is focused on enhancing the cancer treatment experience for patients. Following the initial collaboration, IHH has taken a step further by becoming an equity investor in Leo Cancer Care, underscoring its belief in the promising long-term perspectives of upright therapy solutions.

As the collaboration progresses, IHH is venturing into the proton therapy space as well. This move aims to make the compact Marie® upright proton solution more accessible and economically viable for patients in need of advanced treatments. Traditional issues associated with proton therapy—such as limited adoption due to high costs and infrastructure demands—could be addressed by this innovative upright approach, where the patient rotates instead of the beam, significantly reducing overall system size and expense.

A New Era of Cancer Treatment

Elizabeth Han, the Group Head of Innovation and Transformation at IHH Healthcare, stated, "At IHH, we view technology and innovation as powerful enablers of enhanced patient outcomes and experiences. Through the Upright Photon Alliance, we are redefining cancer care and the future of radiation therapy."

Stephen Towe, CEO of Leo Cancer Care, remarked, "IHH's commitment to upright radiotherapy reflects the potential of our innovative and simplified approach. We are addressing the evolving healthcare needs of tomorrow instead of complicating and increasing the costs associated with radiotherapy."

This collaborative effort marks a pivotal moment in Asian healthcare, highlighting IHH’s leadership in integrating advanced cancer treatment methodologies. The future looks promising, with an aim to deliver healthcare that is both innovative and effective, promoting the idea of Care. For Good.

About IHH Healthcare

IHH Healthcare is recognized as a leading multinational healthcare provider committed to shaping the future of medical care. Driven by its aspiration of 'Care. For Good.', IHH combines medical excellence with innovation across its trusted brands, which include Acibadem, Gleneagles, Fortis, and many others. With a workforce of 70,000 spread across ten countries, including Malaysia, Singapore, Türkiye, and India, IHH delivers world-class medical services through a network of over 140 healthcare facilities, including more than 80 hospitals. IHH Healthcare aims to set new standards in health services while contributing positively to the health ecosystem.

As it continues to engage in pioneering initiatives, IHH's collaboration with Leo Cancer Care stands as a testament to its ongoing mission of creating meaningful impacts in the healthcare landscape.